The global Progressive Fibrosing Interstitial Lung Disease market is currently valued at USD 4742.2 Million in 2023 and is anticipated to expand at a CAGR of 6.2%. Owing to the technological advances in healthcare the market is likely to propel to USD 8654.1 Million by 2033.
The progressive fibrosing interstitial lung disease market is anticipated to increase due to factors such as increased awareness of PF-ILD along with the expected launch of emerging therapies during the forecast period (2023 to 2033).
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | USD 4742.2 Million |
| Projected Forecast Value (2033) | USD 8654.1 Million |
| Global Growth Rate (2023 to 2033) | 6.2% CAGR |
Progressive Fibrosing Interstitial Lung Disease (PF-ILD) consists of a diverse group of interstitial lung diseases (ILDs) characterized by a similar clinical phenotype of accelerated respiratory failure, frequent disease exacerbation, and earlier mortality.
Interstitial lung disease is believed to be caused by long-term exposure to hazardous materials, such as asbestos or coal dust, or it can be caused by an auto-immune disease such as rheumatoid arthritis. Progressive Fibrosing Interstitial Lung Diseases are composed of Idiopathic Interstitial Pneumonias such as non-specific interstitial pneumonia and unclassifiable interstitial pneumonia, and inhalation lung diseases such as chronic hypersensitivity pneumonia, and connective tissue disease-associated ILD such as rheumatoid arthritis-related ILD and SSc-related ILD, and sarcoidosis and so on. Many interstitial lung diseases (ILDs) are characterized by chronic progressive fibrosis.
The type-specific segmentation majorly includes Idiopathic Interstitial Pneumonias (IIPs), Autoimmune ILDs, Hypersensitivity Pneumonitis, Sarcoidosis, and ILDs.
Imaging tests such as X-ray and a high-resolution computed tomography (CT scan), are key to, and sometimes the first step in, the diagnosis of interstitial lung disease. The severity level of Progressive Fibrosing Interstitial Lung Disease is calculated on the basis of the FVC score. However, identifying and determining the cause of interstitial lung disease can be challenging, as a large number of disorders fall into this broad category. Hence differential diagnosis is needed.
PF-ILD treatments that act on the fibrotic pathway are required to slow the progression of fibrosis. Other than IPF, there are few treatment options for advanced fibrotic ILD. Pirfenidone use in PPF patients is associated with a statistically significant reduction in disease progression and protection of lung function.
Explore FMI!
Book a free demo
Growing Incidences of Infections Cause by Coxsackievirus to Drive the Market Growth
Major factors driving the global progressive fibrosing interstitial lung disease treatment market are an increase in the incidence of lung infections, a surge in awareness among the people, and rigorous government initiatives to reduce the incidence of these infections.
Also, the increasing awareness regarding interstitial lung disease treatment among people, availability of cost-effective drugs in the market, and high prevalence of viral infection-causing lung disorder across the globe is expected to be the key factor driving the growth of progressive fibrosing interstitial lung disease treatment market.
The global progressive fibrosing interstitial lung disease treatment market is anticipated to observe impressive growth during the forecast period, 2023 to 2033. The other factors supporting the market’s growth are, the increasing government investments in research & development activities, the growing footprint of pharmaceutical manufacturers, developed healthcare infrastructure, rising awareness among the masses, and technological advancements.
The adoption of Inorganic Strategies by the Market Players is Expected to Drive Market Growth During the Forecast Period.
The increasing number of partnerships by key players is expected to boost the growth of the global interstitial lung disease market during the forecast period. For instance, in September 2020, Boehringer Ingelheim (Canada) Ltd., a pharmaceutical company, announced that they had entered into a partnership with the University Hospital Foundation (UHF), this partnership will focus on improving patient outcomes in the area of progressive fibrosing interstitial lung disease (PF-ILD).
High Expenditures Associated with Progressive Fibrosing Interstitial Lung Disease (PFILD) Treatment Research and Development
Although the progressive fibrosing interstitial lung disease treatment market has numerous end-uses, there are numerous obstacles that likely pose a challenge to market growth. The high cost of drugs for the treatment of lung disease will restrain the growth of this market to some extent.
The high expense of therapies has severely hindered their widespread acceptance, particularly in underdeveloped nations. Such high treatment costs are also a subject of worry in developed nations, as many treatments may not be appropriately reimbursed, raising the patient's out-of-pocket expenditures dramatically.
Some side effects after the consumption of anti-inflammatory drugs will also hinder the growth of the progressive fibrosing interstitial lung disease market. All these factors are expected to derail the progress of the progressive fibrosing interstitial lung disease treatment market.
Many drugs have been withdrawn due to clinical challenges in later stages, implying that current emerging drugs may fail and clinical development failure weakens the emerging pipeline. This will disrupt progressive fibrosing interstitial lung disease treatment market growth.
Other factors such as a lack of sensitive clinical outcomes, suitable biomarkers, and difficulty in recruiting subjects, resulting in project delays or cancellations, are hindering the growth of the progressive fibrosing interstitial lung disease treatment market.
Advancement in Healthcare to Boost the Market Growth in Region
The market in the North American region is anticipated to observe vibrant growth during the forecast period 2023 to 2033. This can be attributed to the growing developments in the healthcare sector as a result of rising research and development activities in this industry. The region is expected to hold the highest CAGR of 6.0% during the forecast period.
The high prevalence of the disease together with the presence of many leading market players in the region is expected to boost the growth of the North American interstitial lung disease treatment market in the years to come.
The highest total diagnosed prevalent cases of Progressive Fibrosing Interstitial Lung Disease were accounted for by the US in 2021 (166,393 cases), which are expected to show a rise in the future.
Growing Prevalence of Lung-Related Disorders to Boost the Growth of the Market
Europe is expected to have the second maximum market share of the progressive fibrosing interstitial lung disease treatment market due to the high number of people suffering from COPD and asthma in the region.
Among the European countries, Germany had the highest total diagnosed prevalent cases of Progressive Fibrosing Interstitial Lung Disease with 31,807 cases, followed by the United Kingdom, which had diagnosed cases of 25,446 in 2021. On the other hand, Spain had the lowest diagnosed population (17,834 cases).
In addition, technologically advanced healthcare facilities are contributing to the growth of the market. Moreover, increasing awareness regarding early therapeutics for lung disease is contributing to the growth of the market. Thus, Europe is expected to possess a 56.7% market share in 2023.
| Countries | CAGR |
|---|---|
| United Kingdom | 6.0% |
| India | 5.6% |
| South Korea | 5.7% |
| China | 5.8% |
| United States of America | 6.1% |
Corticosteroids Segment to Generate Significantly High Revenue
On the basis of drug type progressive fibrosing interstitial lung disease (PFILD) treatment market is classified into Corticosteroids, Immune Suppressing, Anti-Fibrotic Medication, and Others. Among these corticosteroids registers the highest demand in the progressive fibrosing interstitial lung disease treatment market owing to the fewer side effects registered with the usage of this drug as compared to others. Corticosteroids, except nintedanib and pirfenidone, are commonly used as first-line therapies for ILDs other than IPF. Except for acute exacerbations, international guidelines for IPF treatment strongly recommend corticosteroid monotherapy.
The corticosteroids segment held a dominant market share in the year 2023 and is estimated to grow with the fastest CAGR rate of 5.9% over the forecast period 2022to2023.
Hospital Pharmacy Segment Remains Dominant Among Other Types
The hospital pharmacy segment dominated the global market in 2023 with a revenue share of over 65.5%. The growth of the segment is attributed to the increasing prevalence of Progressive Fibrosing Interstitial Lung Disease (PFILD) and hospitalization for treatment.
Hospital pharmacies preserve the stock of products related to Interstitial Lung Disease for out-patients as well as in-patients. The segment will be driven further by growing consumer awareness and increased investments in healthcare infrastructure in developing and underdeveloped countries.
The online pharmacies segment is expected to be the fastest-growing distribution channel segment. This growth can be attributed to user-friendly interfaces and convenience offered by these pharmacies, in terms of access, prices, and delivery. In addition, they have several discounts on purchases of a certain amount or offer bundle pricing for many products.
How do New Entrants Contribute to the Progressive Fibrosing Interstitial Lung Disease (PFILD) Treatment Market?
With technological innovations happening at a rapid pace, and companies looking for ways to increase customer engagement, start-ups are taking all possible steps to establish a name for themselves in the progressive fibrosing interstitial lung diseases treatment market.
Some of the start-ups in the progressive fibrosing interstitial lung diseases treatment market include-
Some of the key players present in the global progressive fibrosing interstitial lung diseases treatment markets are Boehringer Ingelheim, Bristol-Myers Squibb, FibroGen, Hoffmann-La Roche Ltd, Pliant Therapeutics, Inc., United Therapeutics, Vicore Pharma AB, Avalyn Pharmaceuticals, Beijing Continent Pharmaceutical, GNI-EPS Pharmaceuticals, Inc. and others.
The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to market segments such as geographies, applications, and industries.
| Report Attribute | Details |
|---|---|
| Growth Rate | CAGR 6.2% from 2023 to 2033 |
| Expected Market Value (2023) | USD 4742.2 Million |
| Projected Forecast Value (2033) | USD 8654.1 Million |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Billion & CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends & Pricing Analysis |
| Segments Covered | Drug Type, Route of Administration, Distribution Channel, Regions |
| Regions Covered | North America; Latin America; Europe; East Asia; South Asia; Oceania; Middle East and Africa |
| Key Countries Profiled | United States of America, Canada, Brazil, Mexico, Germany, United Kingdom, France, Spain, Italy, India, Malaysia, Singapore, Thailand, Australia, New Zealand, China, Japan, South Korea, GCC Countries, South Africa, Israel |
| Key Companies Profiled | Boehringer Ingelheim; Bristol-Myers Squibb; FibroGen; Hoffmann-La Roche Ltd; Pliant Therapeutics, Inc.; United Therapeutics; Vicore Pharma AB; Avalyn Pharmaceuticals; Beijing Continent Pharmaceutical; GNI-EPS Pharmaceuticals, Inc. |
| Customization | Available Upon Request |
The incidence of diabetic foot ulcers in diabetics and the increasing prevalence of chronic wounds drive market growth.
The market is forecast to register a CAGR of 6.2% through 2033.
Some key players in the global market are Boehringer Ingelheim, Bristol-Myers Squibb, and FibroGen.
The market is estimated to reach USD 8,654.1 million by 2033.
High expenditures associated with progressive fibrosing interstitial lung disease (PFILD) treatment research and development limit growth.
The high prevalence of the disease, together with the presence of many leading market players in the region, is expected to boost the growth.
Digital Scale Market Analysis by Product, Age Group, Modality, End User, and Region 2025 to 2035
The Liquid Biopsy Market Is Segmented by Biomarker Type, Sample Type & End User from 2025 to 2035
The Arthroscopy Procedure and Products Market is segmented by product type, application, and end user from 2025 to 2035
The Liposuction Surgery Devices Market is segmented By Technology and End User from 2025 to 2035
The Positron Emission Tomography (PET) Scanners Market is segmented by Full-ring PET Scanner and Partial-ring PET Scanner from 2025 to 2035
Antibody-mediated Rejection Prevention Market Overview - Growth & Forecast 2025 to 2035
Progressive Fibrosing Interstitial Lung Disease (PFILD) Treatment Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
